Royalty Pharma plc (ticker: RPRX) is an NASDAQ-listed pharma company. DredgeCap's structured extraction of RPRX's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. RPRX reported $630.58M in revenue and $294.69M for the period ending 2026-03-31, with operating cash flow of $718.23M. Cash and equivalents stood at $586.39M (down 46.1% year-over-year). Total assets of $19.82B exceed total liabilities of $9.88B. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
RPRX Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for Royalty Pharma plc (RPRX) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.